BrightGene Bio-Medical Technology Co Ltd
SSE:688166

Watchlist Manager
BrightGene Bio-Medical Technology Co Ltd Logo
BrightGene Bio-Medical Technology Co Ltd
SSE:688166
Watchlist
Price: 31.54 CNY 2.1% Market Closed
Market Cap: 13.3B CNY
Have any thoughts about
BrightGene Bio-Medical Technology Co Ltd?
Write Note

Intrinsic Value

The intrinsic value of one BrightGene Bio-Medical Technology Co Ltd stock under the Base Case scenario is 22.57 CNY. Compared to the current market price of 31.54 CNY, BrightGene Bio-Medical Technology Co Ltd is Overvalued by 28%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
22.57 CNY
Overvaluation 28%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
BrightGene Bio-Medical Technology Co Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BrightGene Bio-Medical Technology Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BrightGene Bio-Medical Technology Co Ltd?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
BrightGene Bio-Medical Technology Co Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about BrightGene Bio-Medical Technology Co Ltd

Provide an overview of the primary business activities
of BrightGene Bio-Medical Technology Co Ltd.

What unique competitive advantages
does BrightGene Bio-Medical Technology Co Ltd hold over its rivals?

What risks and challenges
does BrightGene Bio-Medical Technology Co Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for BrightGene Bio-Medical Technology Co Ltd.

Provide P/S
for BrightGene Bio-Medical Technology Co Ltd.

Provide P/E
for BrightGene Bio-Medical Technology Co Ltd.

Provide P/OCF
for BrightGene Bio-Medical Technology Co Ltd.

Provide P/FCFE
for BrightGene Bio-Medical Technology Co Ltd.

Provide P/B
for BrightGene Bio-Medical Technology Co Ltd.

Provide EV/S
for BrightGene Bio-Medical Technology Co Ltd.

Provide EV/GP
for BrightGene Bio-Medical Technology Co Ltd.

Provide EV/EBITDA
for BrightGene Bio-Medical Technology Co Ltd.

Provide EV/EBIT
for BrightGene Bio-Medical Technology Co Ltd.

Provide EV/OCF
for BrightGene Bio-Medical Technology Co Ltd.

Provide EV/FCFF
for BrightGene Bio-Medical Technology Co Ltd.

Provide EV/IC
for BrightGene Bio-Medical Technology Co Ltd.

Show me price targets
for BrightGene Bio-Medical Technology Co Ltd made by professional analysts.

What are the Revenue projections
for BrightGene Bio-Medical Technology Co Ltd?

How accurate were the past Revenue estimates
for BrightGene Bio-Medical Technology Co Ltd?

What are the Net Income projections
for BrightGene Bio-Medical Technology Co Ltd?

How accurate were the past Net Income estimates
for BrightGene Bio-Medical Technology Co Ltd?

What are the EPS projections
for BrightGene Bio-Medical Technology Co Ltd?

How accurate were the past EPS estimates
for BrightGene Bio-Medical Technology Co Ltd?

What are the EBIT projections
for BrightGene Bio-Medical Technology Co Ltd?

How accurate were the past EBIT estimates
for BrightGene Bio-Medical Technology Co Ltd?

Compare the revenue forecasts
for BrightGene Bio-Medical Technology Co Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of BrightGene Bio-Medical Technology Co Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of BrightGene Bio-Medical Technology Co Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of BrightGene Bio-Medical Technology Co Ltd compared to its peers.

Compare the P/E ratios
of BrightGene Bio-Medical Technology Co Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing BrightGene Bio-Medical Technology Co Ltd with its peers.

Analyze the financial leverage
of BrightGene Bio-Medical Technology Co Ltd compared to its main competitors.

Show all profitability ratios
for BrightGene Bio-Medical Technology Co Ltd.

Provide ROE
for BrightGene Bio-Medical Technology Co Ltd.

Provide ROA
for BrightGene Bio-Medical Technology Co Ltd.

Provide ROIC
for BrightGene Bio-Medical Technology Co Ltd.

Provide ROCE
for BrightGene Bio-Medical Technology Co Ltd.

Provide Gross Margin
for BrightGene Bio-Medical Technology Co Ltd.

Provide Operating Margin
for BrightGene Bio-Medical Technology Co Ltd.

Provide Net Margin
for BrightGene Bio-Medical Technology Co Ltd.

Provide FCF Margin
for BrightGene Bio-Medical Technology Co Ltd.

Show all solvency ratios
for BrightGene Bio-Medical Technology Co Ltd.

Provide D/E Ratio
for BrightGene Bio-Medical Technology Co Ltd.

Provide D/A Ratio
for BrightGene Bio-Medical Technology Co Ltd.

Provide Interest Coverage Ratio
for BrightGene Bio-Medical Technology Co Ltd.

Provide Altman Z-Score Ratio
for BrightGene Bio-Medical Technology Co Ltd.

Provide Quick Ratio
for BrightGene Bio-Medical Technology Co Ltd.

Provide Current Ratio
for BrightGene Bio-Medical Technology Co Ltd.

Provide Cash Ratio
for BrightGene Bio-Medical Technology Co Ltd.

What is the historical Revenue growth
over the last 5 years for BrightGene Bio-Medical Technology Co Ltd?

What is the historical Net Income growth
over the last 5 years for BrightGene Bio-Medical Technology Co Ltd?

What is the current Free Cash Flow
of BrightGene Bio-Medical Technology Co Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for BrightGene Bio-Medical Technology Co Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
BrightGene Bio-Medical Technology Co Ltd

Current Assets 1.4B
Cash & Short-Term Investments 505.4m
Receivables 374.8m
Other Current Assets 502.3m
Non-Current Assets 3.5B
Long-Term Investments 244m
PP&E 2.7B
Intangibles 107.6m
Other Non-Current Assets 423.8m
Current Liabilities 885.5m
Accounts Payable 174.1m
Accrued Liabilities 14.6m
Short-Term Debt 161.9m
Other Current Liabilities 534.9m
Non-Current Liabilities 1.6B
Long-Term Debt 1.6B
Other Non-Current Liabilities 68m
Efficiency

Earnings Waterfall
BrightGene Bio-Medical Technology Co Ltd

Revenue
1.2B CNY
Cost of Revenue
-559.1m CNY
Gross Profit
682.4m CNY
Operating Expenses
-476.2m CNY
Operating Income
206.2m CNY
Other Expenses
-18.1m CNY
Net Income
188.1m CNY

Free Cash Flow Analysis
BrightGene Bio-Medical Technology Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

BrightGene Bio-Medical Technology Co Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Operating Income
Positive Net Income
Positive Revenue Growth Forecast
50/100
Profitability
Score

BrightGene Bio-Medical Technology Co Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

BrightGene Bio-Medical Technology Co Ltd's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Low D/E
Short-Term Solvency
59/100
Solvency
Score

BrightGene Bio-Medical Technology Co Ltd's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
BrightGene Bio-Medical Technology Co Ltd

Wall Street analysts forecast BrightGene Bio-Medical Technology Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BrightGene Bio-Medical Technology Co Ltd is 45.09 CNY with a low forecast of 44.65 CNY and a high forecast of 46.42 CNY.

Lowest
Price Target
44.65 CNY
42% Upside
Average
Price Target
45.09 CNY
43% Upside
Highest
Price Target
46.42 CNY
47% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BrightGene Bio-Medical Technology Co Ltd?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BrightGene Bio-Medical Technology Co Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

BrightGene Bio-Medical Technology Co Ltd Logo
BrightGene Bio-Medical Technology Co Ltd

Country

China

Industry

Pharmaceuticals

Market Cap

13.3B CNY

Dividend Yield

0%

Description

BrightGene Bio-Medical Technology Co., Ltd. engages in the research, development, and manufacturing of biopharmaceuticals, medicines as well as special generic active pharmaceutical ingredients and finished dosage forms. The company is headquartered in Suzhou, Jiangsu and currently employs 910 full-time employees. The company went IPO on 2019-11-08. The firm's main products include antifungal active pharmaceutical ingredients (APIs), antiviral APIs, immunosuppressive APIs, and other APIs and preparations. The firm's generic drugs mainly include entecavir, caspofungin, micafungin, posaconazole, everolimus and fondaparinux sodium. The firm mainly conducts its businesses in domestic and overseas markets.

Contact

JIANGSU
Suzhou
Building C25-C28, Nano Technology Park, No.218 Xinghu Street, Suzhou Industry Park
+8651262620988
www.bright-gene.com

IPO

2019-11-08

Employees

910

Officers

Chairman & GM
Mr. Jiandong Yuan
Chief Financial Officer
Mr. Yuanlai Zou
Board Secretary
Ms. Nan Ding
Deputy General Manager
Mr. Kai Li
Accounting Supervisor
Fang Liu

See Also

Discover More
What is the Intrinsic Value of one BrightGene Bio-Medical Technology Co Ltd stock?

The intrinsic value of one BrightGene Bio-Medical Technology Co Ltd stock under the Base Case scenario is 22.57 CNY.

Is BrightGene Bio-Medical Technology Co Ltd stock undervalued or overvalued?

Compared to the current market price of 31.54 CNY, BrightGene Bio-Medical Technology Co Ltd is Overvalued by 28%.

Back to Top